CNSY
Plus Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$2.78
−6.71%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.2M | 5.2M | 5.8M | 4.9M | 224.0K |
| Cost of Revenue | 438.0K | 445.0K | 852.0K | 9.7M | 712.0K |
| Gross Profit | 3.8M | 4.8M | 5.0M | (4.8M) | (488.0K) |
| Operating Expenses | |||||
| R&D Expense | 12.5M | 8.4M | 10.6M | 9.7M | 9.7M |
| SG&A Expense | 17.9M | 12.1M | 9.9M | 8.5M | 9.5M |
| General & Admin Expense | 12.9M | 12.1M | 9.9M | 8.5M | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (287.0K) | (445.0K) | (852.0K) | (9.7M) | — |
| Total Operating Expenses | 30.2M | 20.1M | 19.7M | 8.5M | 19.2M |
| Cost and Expenses | 30.6M | 20.5M | 20.5M | 18.2M | 19.9M |
| Operating Income (EBIT) | (26.4M) | (15.3M) | (14.7M) | (13.3M) | (19.7M) |
| Non-Operating | |||||
| Interest Income | 334.0K | 116.0K | 273.0K | 400.0K | 147.0K |
| Interest Expense | 3.1M | 3.6M | 3.7M | 395.0K | 711.0K |
| Net Interest Income | (2.7M) | (3.5M) | (3.5M) | 5.0K | (564.0K) |
| Other Non-Op Income/Expense | 312.0K | (7.1M) | 1.7M | 5.0K | (563.0K) |
| Non-Operating Income (excl Interest) | (3.6M) | 3.5M | (5.4M) | (400.0K) | (148.0K) |
| EBT (Pre-Tax Income) | (26.1M) | (22.4M) | (13.0M) | (13.3M) | (20.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (26.1M) | (22.4M) | (13.0M) | (13.3M) | (20.3M) |
| Earnings from Cont. Ops | (26.1M) | (22.4M) | (13.0M) | (13.3M) | (20.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (26.1M) | (22.4M) | (18.0M) | (13.3M) | (20.3M) |
| Per Share | |||||
| Basic EPS | ($1,033.42) | ($7.19) | ($48.75) | ($106,000.00) | ($288,750.00) |
| Diluted EPS | ($4.43) | ($7.19) | ($58.50) | ($106,000.00) | ($288,750.00) |
| Revenue Per Share | $0.62 | $1.68 | $21.93 | $39,104.72 | $3,199.36 |
| Shares | |||||
| Basic Shares Outstanding | 6.8M | 3.1M | 265610 | 126 | 70 |
| Diluted Shares Outstanding | 6.8M | 3.1M | 308030 | 126 | 70 |
| Profitability Metrics | |||||
| EBITDA | (22.4M) | (18.3M) | (8.4M) | (12.3M) | (18.9M) |
| D&A | 403.0K | 445.0K | 852.0K | 628.0K | 712.0K |
| EBIT | (22.8M) | (18.8M) | (9.3M) | (12.9M) | (19.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026